Latest:
Montefiore Einstein Comprehensive Cancer Center Upholds Top Honor for Cancer Care
MECCC Earns Three-Year Accreditation from the Commission on Cancer of the American College of Surgeons – Again!
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Diva Baggio, MBBS
Diva Baggio, MBBS, is a Margaret Spittle CNS Lymphoma Research Fellow at University College London Hospitals NHS Foundation Trust
Latest:
Dr Baggio on Prognostic Patterns of CNS Relapse in LBCL
Diva Baggio, MBBS, discusses findings from an international, multicenter study evaluating relapse patterns in patients with CNS relapse of LBCL.
Dejan Juric, MD, Massachusetts General Hospital
Latest:
Future Directions for the Management of HR+ Breast Cancer
Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.
Andrew Laccetti, MD, MS
Latest:
Dr Laccetti on PSA Responses With Masofaniten Plus Enzalutamide in mCRPC
Andrew Laccetti, MD, MS, discusses phase 1 findings from a phase 1/2 trial investigating masofaniten in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.
Ori Barzilai, MD
Latest:
Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two Decades
Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.
Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB
Latest:
Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma
Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.
Nicholas Coupe, MBBS, PhD
Latest:
Dr Coupe on the Background of IMM60 With Pembrolizumab in Melanoma or NSCLC
Nicholas Coupe, MBBS, PhD, discusses the rationale for investigating IMM60 with pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer, as well as key background information that led to this investigation.
Amanda Blackmon, DO
Latest:
Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML
The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.
Bijal Shah, MD, MS
Bijal Shah, MD, MS, is an associate member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida.
Latest:
Obe-Cel Data Are Poised to Refine and Expand the ALL Treatment Paradigm: With Aaron Logan, MD, PhD; and Bijal Shah, MD, MS
Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm and how the use of this agent might expand going forward.
Robert Cameron, MD, PhD
Robert Cameron, MD, PhD, is a Hematology/Oncology fellow at the University of Chicago.
Latest:
Dr Cameron on the Prognostic Value of PD-L1 for Outcomes With Osimertinib in EGFR+ NSCLC
Robert Cameron, MD, PhD, discusses a study examining the impact of PD-L1 expression on outcomes with osimertinib in EGFR-mutated NSCLC.